[4-(2-Phenyl-imidazol-1-yl)-pyrimidin-2-yl]-m-tolyl-amine

ID: ALA47832

Chembl Id: CHEMBL47832

PubChem CID: 5329415

Max Phase: Preclinical

Molecular Formula: C20H17N5

Molecular Weight: 327.39

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  Cc1cccc(Nc2nccc(-n3ccnc3-c3ccccc3)n2)c1

Standard InChI:  InChI=1S/C20H17N5/c1-15-6-5-9-17(14-15)23-20-22-11-10-18(24-20)25-13-12-21-19(25)16-7-3-2-4-8-16/h2-14H,1H3,(H,22,23,24)

Standard InChI Key:  FAGREBOKSNRJQA-UHFFFAOYSA-N

Alternative Forms

Associated Targets(Human)

KDR Tclin Vascular endothelial growth factor receptor 2 (20924 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
FLT1 Tclin Vascular endothelial growth factor receptor (287 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PDGFRB Tclin VEGF-receptor 2 and PDGF-receptor beta (KDR and PDGFR beta) (29 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
FLT1 Tclin Vascular endothelial growth factor receptor 1 and 2 (Flt-1 and KDR) (27 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
FLT4 Tclin Vascular endothelial growth factor receptor 2 and 3 (KDR and Flt-4) (23 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
KDR Tclin VEGF-receptor 2 and Fibroblast growth factor receptor 1 (50 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
KDR Tclin VEGF-receptor 2 and Fibroblast growth factor receptor 2 (15 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SRC Tclin VEGF-receptor 2 and tyrosine-protein kinase SRC (25 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 327.39Molecular Weight (Monoisotopic): 327.1484AlogP: 4.38#Rotatable Bonds: 4
Polar Surface Area: 55.63Molecular Species: NEUTRALHBA: 5HBD: 1
#RO5 Violations: HBA (Lipinski): 5HBD (Lipinski): 1#RO5 Violations (Lipinski):
CX Acidic pKa: 13.48CX Basic pKa: 5.29CX LogP: 5.06CX LogD: 5.06
Aromatic Rings: 4Heavy Atoms: 25QED Weighted: 0.60Np Likeness Score: -1.66

References

1. Manley PJ, Balitza AE, Bilodeau MT, Coll KE, Hartman GD, McFall RC, Rickert KW, Rodman LD, Thomas KA..  (2003)  2,4-disubstituted pyrimidines: a novel class of KDR kinase inhibitors.,  13  (10): [PMID:12729639] [10.1016/s0960-894x(03)00244-0]

Source